Viva Biotech : CHANGE OF CHIEF FINANCIAL OFFICER

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

VIVA BIOTECH HOLDINGS

維亞生物科技控股集團

(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

CHANGE OF CHIEF FINANCIAL OFFICER

Viva Biotech Holdings (the "Company") together with its subsidiaries, the "Group") announces that Mr. WANG Zheren ("Mr. Wang") will be appointed as the chief financial officer of the Company in place of Mr. HUA Fengmao ("Mr. Hua") with effect from April 29, 2021.

Mr. Hua, an executive director (the "Director") of the Company has notified the Company that he will cease to be Company's chief financial officer with effect from April 29, 2021. Mr. Hua will remain as an executive Director and participate in the day-to-day management of the Group and he will continue to hold his other positions in the board of Directors (the "Board") of the Company and the Group. Mr. Hua ceases to be the Company's chief financial officer in order to devote more time to other businesses of the Group. Mr. Hua has confirmed that that he has no disagreement with the Board and that there is no matter that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

The Company is pleased to announce that Mr. Wang, aged 37, who joined our Group in April 2021, will be appointed as the chief financial officer of the Company with effect from April 29, 2021. Prior to joining the Group, he was the chief operation officer and chief financial officer of MITRO Biotech Co., Ltd. ( 米

度 ( 南京) 生物技術有限公司) from July 2016 to March 2021. From November 2010 to July 2016, he was a partner with AVISTA Group, a financial advisory firm headquartered in Hong Kong. He worked in the assurance department and advisory department of PricewaterhouseCoopers from July 2005 to October 2010.

Mr. Wang graduated from the Shanghai University of Finance and Economics ( 上海財經大學) with a double degree in economics and management in 2005 and is also a CFA Charterholder.

- 1 -

The Company wishes to express its appreciation to Mr. Hua for his valuable contribution to the Group during his tenure of office as the Company's chief financial officer and also welcomes Mr. Wang to the new appointment.

By order of the Board

Viva Biotech Holdings

Mao Chen Cheney

Chairman and Chief Executive Officer

Hong Kong, April 26, 2021

As at the date of this announcement, the Board comprises four Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying, Mr. Hua Fengmao and Mr. Ren Delin; a Non-executive Directors, namely, Ms. Sun Yanyan; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.

- 2 -